BIOCHEMICAL CRITERIA FOR ASSESSMENT OF KIDNEY FUNCTION IN PATIENTS WITH PLASMA CELL MYELOMA SUFFERED AFTER THE CHORNOBYL ACCIDENT

  • Tatiana Liubarets ДУ «Національний науковий центр радіаційної медицини Національної академії медичних наук України», Київ
Keywords: Plasma cell myeloma, kidney function, victims of the Chornobyl accident

Abstract

The aim of the work was to study the peculiarities of biochemical parameters of renal function in plasma cell myeloma patients suffered after the Chornobyl accident.
Materials and Methods. The peculiarities of the disease course in 64 patients with plasma cell myeloma (PCM), who were examined and treated in the Department of Radiation Oncohematology of State institution «Natinal Research Center for Radiation Medicine of NAMS of Ukraine» during 2010-2017 were analyzed. The main clinical and laboratory characteristics of PCM were evaluated (LDH, β2-microglobulin, albumin, serum calcium, urea, creatinine and hemoglobin level) in connection with radiation history (participants of the Chornobyl accident clean up activity, evacuees from the zones of resettlement, residents of contaminated territories and group comparison), the PCM stages according to the classifications of Durie-Salmon et al. (1975) and ISS (1985).
Results and conclusion. It was found that in PCM patients with a burdened radiation history, compared to non-irradiated patients, the level of β2-micro-globulin (p = 0.02) and calcium (p = 0.04) was significantly increased in. It was confirmed that the most informative characteristics in PCM patients are urea (F = 3.58; p = 0.05) and serum albumin (F = 4.00; p = 0.05). Significant correlation of the main parameters characterizing the renal function in PCM patients with the anemia and the level of calcium, which depends on the degree of osteolytic bone damage, was confirmed. Differences in clinical and hematological signs in PCM patients suffered after the Chornobyl accident and non-irradiated persons have been revealed and formed the basis for predicting the effectiveness of treatment that need further research in this area.

References

1. Swerdlow S.H., Campo E., Pileri S.A , Harris N.L, Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., Jaffe E.S. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016. Vol. 27. – Р. 2375-2390
2. Leuraud K., Richardson D.B., Cardis E., Daniels R.D., Gillies M., O’Hagan J.A., Hamra G.B., Haylock R., Laurier D., Moissonnier M., Schubauer-Berigan M.K., Thierry-Chef I., Kesminiene A. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. The Lancet Haematology. 2015. Vol. 2, № 7. Р. 276-281.
3. Rudzianskiene M., Inciura A., Juozaityte E., Gerbutavicius R., Simoliuniene R., Rudzianskas V., Kiavialaitis G.E. The impact of one fraction of 8 Gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions. Turkish Journal of Medical Sciences. 2015. Vol. 45, № 2. Р. 364-371.
4. Rudzianskiene M., Inciura A., Gerbutavicius R., Rudzianskas V., Macas A., Simoliuniene R., Dambrauskiene R., Kiavialaitis G. E., Juozaityte E. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study. Strahlentherapie Onkologie. 2017. – Vol. 193, – № 9. – Р. 742-749.
5. Durie B. G. International Myeloma Working Group 2003 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. – 2003. – Vol. 121. – P. 749–757.
6. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975. – Vol. 36. – P. 842-854.
7. Greipp P.R., San Miguel .J., Durie B.G., Crowley J.J., Barlogie B., Blade′ J., Boccadoro M., Child J.A. International staging system for multiple myeloma / P. R. Greipp et al. J. Clin. Oncol. – 2005. – Vol. 23, № 5. – P. 3412-3420.
8. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009. – Vol. 23, – № 12. – P. 2210-2221.
Published
2020-03-19
How to Cite
Liubarets, T. (2020). BIOCHEMICAL CRITERIA FOR ASSESSMENT OF KIDNEY FUNCTION IN PATIENTS WITH PLASMA CELL MYELOMA SUFFERED AFTER THE CHORNOBYL ACCIDENT. Actual Problems of Nephrology, 25, 41-45. https://doi.org/10.37321/nefrology.2019.25-07